SXTC China SXT Pharmaceuticals, Inc.
Financings ·
China SXT and the purchasers in its October 8, 2026 registered direct offering agreed to cancel, in full, a right to buy up to $12 million more shares. The company says the offering's securities already issued are not affected.
The July 3, 2026 agreement allows pre-paid purchases of up to $31,500,000 before an original issue discount. The August 27 amendment restores the $0.20 floor after a 1-for-80 share consolidation had raised it to $16.00.
China SXT sold 10,000,000 shares with two warrants each for a combined $0.51 a share. The warrant exercise price resets to $0.24 on the seventh day, and the warrants could cover up to 100,000,000 shares. No placement agent or underwriter was used.
The January 21, 2025 agreement sells up to $2,840,000 of shares at $0.20 each, with warrants for 200 percent of each buyer's shares at $1.00. It also sets a penalty of 2.0 percent of the subscription amount for public information failures.
China SXT Pharmaceuticals, Inc. is an offshore holding company that conducts all of its business through its subsidiaries and a variable interest entity, Taizhou Suxuantang, in China. It describes itself as an innovative pharmaceutical company based in China that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine products, called TCMP. The company says its TCMP products are generic drugs whose origin, quality standard and dosage are documented in the China Pharmacopoeia. It sells three types: Advanced TCMP, which requires specialized equipment and more manufacturing steps; Fine TCMP, made with more refined ingredients; and Regular TCMP. The company reports that it has produced and marketed 11 Advanced TCMPs, has 5 Fine TCMPs and 200 Regular TCMPs, and has 200 raw medicinal materials. For the fiscal year ended March 31, 2026, Regular TCMP contributed 95.02% of total revenue and Advanced TCMP contributed 4.35%.
| Product or program | What it is | Stage |
|---|---|---|
| Advanced TCMP | Traditional Chinese Medicine product requiring specialized equipment and more manufacturing steps | |
| Fine TCMP | Traditional Chinese Medicine product made with more refined ingredients than Regular TCMP | |
| Regular TCMP | Traditional Chinese Medicine product, the largest share of revenue |
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Net income (loss) | -$6.2 million | -$3.3 million |
| Cash from operations | -$4.0 million | -$2.3 million |
| Cash and equivalents | $28.2 million | $18.1 million |
Our latest story on this, dated Oct 21, 2026: "China SXT ends purchasers' right to buy up to $12 million more shares". The story links the filing or release it is based on. Read the story.
China SXT Pharmaceuticals, Inc. trades under the ticker SXTC on NASDAQ.
China SXT Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for China SXT Pharmaceuticals, Inc. is 1723980. Its filings are on SEC EDGAR.
958,077 shares as of 2026-03-31, per the cover page of its 20-F filed 2026-07-01.
Our directory records China SXT Pharmaceuticals, Inc. under China.
Our directory classifies China SXT Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for China SXT Pharmaceuticals, Inc. is VGG2161P1734.
aibio.space lists China SXT Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as D8.
China SXT Pharmaceuticals, Inc. is an offshore holding company that conducts all of its business through its subsidiaries and a variable interest entity, Taizhou Suxuantang, in China. It describes itself as an innovative pharmaceutical company based in China that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine products, called TCMP.
Advanced TCMP: Traditional Chinese Medicine product requiring specialized equipment and more manufacturing steps
Fine TCMP: Traditional Chinese Medicine product made with more refined ingredients than Regular TCMP
China SXT Pharmaceuticals, Inc. reported a net loss of $6.2 million for the fiscal year ended Mar 31, 2026, and used $4.0 million of cash in operations, per its annual report to the SEC.
$28.2 million in cash at Mar 31, 2026, per its 20-F.
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio